CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, today announced that it will make a presentation at the 38th Annual J.P. Morgan Healthcare Conference. The company will provide a corporate update on Wednesday, January 15, 2020 at 4:30 pm PT at the Westin St. Francis in San Francisco.
About Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a clinical stage company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate’s lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to PD-1 therapy in some patients. Checkmate is a privately held company headquartered in Cambridge, MA. Additional information regarding Checkmate is available at www.checkmatepharma.com.
